Loading...
•
Jun 30, 2024
Aura Biosciences Q2 2024 Earnings Report
Reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights.
Key Takeaways
Aura Biosciences reported its Q2 2024 financial results, highlighting progress across its clinical programs, especially in the bladder cancer clinical trial. The company anticipates presenting early NMIBC data in October 2024. With a strong cash position, Aura believes it can fund operations into the second half of 2026.
Plans to present early data in Non-muscle Invasive Bladder Cancer (NMIBC) from ongoing Phase 1 trial at a Urologic Oncology Investor Event in October 2024.
Phase 2 end of study data evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-stage Choroidal Melanoma to be presented at Retina Society Annual Meeting.
Cash and cash equivalents and marketable securities totaled $187.4 million as of June 30, 2024.
Current cash position is expected to fund operations into the second half of 2026.
Aura Biosciences
Aura Biosciences
Forward Guidance
Aura Biosciences is focused on advancing its clinical trials in ocular and urologic oncology and anticipates presenting clinical data in the near future.
Positive Outlook
- Plans to share early data in NMIBC at a virtual urologic oncology investor event in October 2024.
- Phase 2 end of study data in small choroidal melanoma and indeterminate lesions will be presented at the Retina Society Annual Meeting in September 2024.
- Company is on track to initiate a Phase 2 trial in metastases to the choroid in 2024.
- CoMpass trial continues to progress globally with site activations and patient enrollment.
- Bel-sar has the potential to selectively treat and induce a tumor specific immune response.
Challenges Ahead
- Uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials.
- Risk that the results of Aura’s preclinical and clinical trials may not be predictive of future results in connection with future clinical trials.
- Risk that interim data from ongoing clinical trials may not be predictive of final data from completed clinical trials.
- Risk that governmental authorities may disagree with Aura’s clinical trial designs.
- Whether Aura’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements.